Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Derms Development Ltd., York Pharma deal

YRK acquired Derms for £17.5 million ($35.7 million) in stock. YRK, which develops dermatology therapies and

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE